Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 9:18 Level 2

<< Previous

Bullboard Posts

Next >>

Post by cra1gBon Mar 02, 2021 9:18am

199 Views

Post# 32693436

9:18 Level 2

$0.075	2333000	74	$0.075	1349000	17
$0.07	1255000	45	$0.08	1518000	21
$0.065	604000	23	$0.085	1444000	21
$0.06	547000	19	$0.09	1040000	27
$0.055	730000	14	$0.095	1652000	19
$0.05	956000	24	$0.10	2913000	46
$0.045	750000	9	$0.105	1636000	13
$0.04	922000	13	$0.11	2325000	41
$0.035	985000	12	$0.115	275000	6
$0.03	1022000	23	$0.12	1359000	33